Effect of r-interferon alpha administration on hypothalamus-pituitary-thyroid axis in chronic hepatitis

• Published in: Life sciences (1973) 1997, Vol.60 (1), p.43-50
• Main Authors: Falaschi, P., D'Urso, R., Proietti, A., Martocchia, A., Pastore, R., Angelucci, L.
• Format: Article
• Language: English
• Subjects: Adult; Aged; Autoantibodies - blood; autoimmunity; Female; hepatitis; Hepatitis B - metabolism; Hepatitis B - therapy; Hepatitis C - metabolism; Hepatitis C - therapy; Hepatitis, Chronic - metabolism; Hepatitis, Chronic - therapy; Humans; interferon alpha; Interferon Type I - therapeutic use; Male; Middle Aged; Recombinant Proteins; thyroid; Thyroid Hormones - metabolism; Thyrotropin - metabolism; Thyroxine - metabolism; Triiodothyronine - metabolism
• ISSN: 0024-3205; 1879-0631
• DOI: 10.1016/S0024-3205(96)00587-5

Recent studies pointed out the development of autoimmune thyroid diseases during Interferon (IFN) therapy, mainly in patients with positive thyroid autoantibodies (MsAb and TgAb) before treatment. The effects of recombinant human IFN alpha (rhIFNalpha) on thyroid function and thyroid autoantibodies were studied in 12 patients with chronic active hepatitis associated with virus B or C, selected on the basis of negative results for MsAb and TgAb. No significant variation in T3, T4 and TSH levels was observed either after the first administration of rhIFN alpha (3 million IU i.m.) or after three months of therapy (3 million IU i.m. 3 times a week). TSH response to TRH was in the normal range either before or after the therapy. The absence of MsAb and TgAb was confirmed in all the patients at the end of the treatment. These results indicate that no patient developed thyroid disorder during IFN therapy. Nevertheless, since positive MsAb and TgAb have been considered as a risk factor for thyroid diseases, in patients selected for IFN therapy they should be carefully assessed for autoantibodies before undergoing IFN treatment.